Neurocrine Biosciences, Inc. (NBIX) — Analyst outlook / Analyst consensus target is. Based on 36 analyst ratings, the consensus is bullish — 31 Buy, 5 Hold.
The consensus price target is $173.67 (low: $140.00, high: $220.00), representing an upside of 32.8% from the current price $130.81.
Analysts estimate Earnings Per Share (EPS) of $3.95 and revenue of $2.36B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $3.40 vs est $3.95 (missed -14%). 2025: actual $4.81 vs est $5.04 (missed -4.5%). Analyst accuracy: 90%.
NBIX Stock — 12-Month Price Forecast
$173.67
▲ +32.77% Upside
Average Price Target
Based on 36 Wall Street analysts offering 12-month price targets for Neurocrine Biosciences, Inc., the average price target is $173.67, with a high forecast of $220.00, and a low forecast of $140.00.
The average price target represents a +32.77% change from the last price of $130.81.
Highest Price Target
$220.00
Average Price Target
$173.67
Lowest Price Target
$140.00
NBIX Analyst Ratings
Buy
Based on 36 analysts giving stock ratings to Neurocrine Biosciences, Inc. in the past 3 months
EPS Estimates — NBIX
90%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $3.40
vs Est $3.95
▼ 16.3% off
2025
Actual $4.81
vs Est $5.04
▼ 4.7% off
Profitability Outlook
Company is profitable with solid earnings. EPS trend is improving.
Revenue Estimates — NBIX
100%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $2.355B
vs Est $2.356B
▼ 0.1% off
2025
Actual $2.861B
vs Est $2.845B
▲ 0.6% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
